u/Avish_Golakiya · 3h ago7 prior · awaiting results
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
Bamzireotide navoxetan, an alpha emitter in neuroendocrine tumours, will headline at ESMO Oct 23 with updated Phase 1/2a data from 76 patients. CATX has 33 months of runway funded through Phase 3 and is the author's favorite among the three ESMO plays.
Now $3.1316m ago